Boss Magazine: Light at the End of the Tunnel – Psychedelic-Assisted Therapy nears FDA Approval

Summary: Boss Magazine recognizes the groundbreaking accomplishments within the psychedelic science community, highlighting MAPS’ work with MDMA-assisted therapy.

 “The notion of drugs such as MDMA and psilocybin, both still listed on Schedule I under the Controlled Substances Act, becoming widely available for mental health treatment was unthinkable even a few years ago. But clinical trials have progressed nicely, and the FDA could approve MDMA and psilocybin for the treatment of PTSD and depression by the summer of 2024,” writes Boss Magazine.

Originally appearing here (Archived)